- Company
- Drug industry back on full alert as COVID-19 cases resurge
- by Aug 21, 2020 06:26am
- The pharmaceutical industry is on full alert again as the confirmed cases of novel coronavirus infection (COVID-19) is resurging rapidly around Seoul metropolitan area. Some companies have already reinitiated emergency working system with employees working in shifts or from home. The South Korean government has recently decided to toughen th
- Company
- Companies are worried about a sharp decline in Rx drug sales
- by Chon, Seung-Hyun Aug 20, 2020 06:24am
- Pharmaceutical companies are again tense with COVID-19. The prescription drug market suffered a temporary sluggishness due to the aftermath of COVID-19, and while it is recovering, the market has contracted again and is worried. Business activities can be greatly affected by the spread of telecommuting. According to UBIST on the 19th, the tot
- Company
- Big 5 except Severance clear Novartis’ Kisqali prescription
- by Eo, Yun-Ho Aug 19, 2020 06:28am
- South Korean general hospitals are ready to prescribe a third cyclin-dependent kinase (CDK) 4/6 inhibitor Kisqali approved after Ibrance and Verzenio. According to the related industry sources, Novartis’ Kisqali (ribocilib) has passed drug committees (DC) at all Big Five general hospitals&8212;Samsung Medical Center, Seoul National Uni
- Company
- Daewoong signs an export contract for Fexuprazan
- by Kim, Jin-Gu Aug 19, 2020 06:28am
- Daewoong announced on the 14th that it has signed an export contract with EMS in Brazil for the P-CAB-affiliated gastric secretion inhibitor Fexuprazan. The contract amount is $72.58 million. EMS will be responsible for the local approval of Fexuprazan in Brazil. The export is expected to proceed in earnest after obtaining permission to B
- Company
- “Safe, effective and convenient Zejula for ‘all-comers'"
- by Eo, Yun-Ho Aug 18, 2020 06:03am
- Different drugs in a same class can have different indications. It could be a development strategy by pharmaceutical companies or a Columbus’ egg. But clearly, the respective companies would try to appeal for different indications in different prescription area and relevant benefit proven from safety and efficacy data. Two poly ADP-
- Company
- Competition of Humira biosimilars intensifies
- by Kim, Jin-Gu Aug 18, 2020 06:03am
- Celltrion and LG Chem compete in earnest in the biosimilar market of Humira (Adalimumab). Both companies have completed phase III clinical trials and are currently working on preliminary work to apply for product approval. If Samsung Bioepis, which has already obtained approval for the product, releases its product early next year, competi
- Company
- Ezetimibe combo drug market grows steeply amid COVID-19
- by Chon, Seung-Hyun Aug 18, 2020 06:02am
- In the dyslipidemia treatment market, the volume of ezetimibe combination drug prescription is expanding rapidly. Preference in prescribing ezetimibe combined with rosuvastatin or atorvasutatin is growing fast. Hanmi Pharmaceutical’s Rosuzet and MSD’s Atozet seem to be leading the steep increase in the use of ezetimibe combination therapy.
- Company
- The safety of Statin therapy has been proven
- by Nho, Byung Chul Aug 14, 2020 03:17pm
- As the Cerebral Cardiovascular Disease Control Act was revised in April, dyslipidemia was included in the range of cerebrovascular diseases under the current law, along with hypertension and diabetes. It is explained that the severity and risk of dyslipidemia have been recognized at the national level and the willingness to support is indicat
- Company
- Zejula, re-challenges 'all comer' for ovarian cancer
- by Eo, Yun-Ho Aug 14, 2020 06:23am
- The anticancer drug 'Zejula' once again challenges 'all comer' insurance benefit through the first line maintenance therapy for ovarian cancer. According to related industries, Takeda Korea recently introduced epithelial ovarian cancer or fallopian tubes that showed a complete or partial response to primary platinum-based chemotherapy rega
- Company
- Bukwang, registered a patent for COVID-19 tx of Levovir
- by Aug 14, 2020 06:21am
- Bukwang Pharm announced on the 11th that it has registered a patent of COVID-19 of antiviral drug 'Levovir' which is for “Use of L-nucleoside to treat COVID-19”. Bukwang Pharm used Remdesivir as a positive control to confirm the effect in human lung cells. And the company explained that it was also effective in a test conducted on monkey k
